12:00 AM
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Livatag doxorubicin Transdrug: Updated Phase II/III data

Updated data from the Phase II portion of a European Phase II/III trial in an undisclosed number of patients with advanced HCC showed that Livatag led to a median survival of 32 months vs. 15 months for patients receiving standard of care (SOC; transarterial chemoembolization...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >